文献リスト

1) Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest. 2007; 117: 1175-83

2) Mantovani A, Allavena P, Sica A, et al. Cancer-related inflammation. Nature. 2008; 454: 436-44

3) Kiyosawa K, Umemura T, Ichijo T, et al. Hepatocellular carcinoma: recent trends in Japan. Gastroenterology. 2004; 127: S17-26

4) Ikeda K, Marusawa H, Osaki Y, et al. Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study. Ann Intern Med. 2007; 146: 649-56

5) Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum. 1994; 61: 1-241

6) Chiba T, Seno H, Marusawa H, et al. Host factors are important in determining clinical outcomes of Helicobacter pylori infection. J Gastroenterol. 2006; 41: 1-9

7) Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002; 347: 417-29

8) Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001; 48: 526-35

9) Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med. 2004; 10: 789-99

10) Ionov Y, Peinado MA, Malkhosyan S, et al. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature. 1993; 363: 558-61

11) Fishel R, Lescoe MK, Rao MR, et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell. 1993; 75: 1027-38

12) Cascalho M. Advantages and disadvantages of cytidine deamination. J Immunol. 2004; 172: 6513-8

13) Lau PP, Villanueva H, Kobayashi K, et al. A DnaJ protein, apobec-1-binding protein-2, modulates apolipoprotein B mRNA editing. J Biol Chem. 2001; 276: 46445-52

14) Anant S, MacGinnitie AJ, Davidson NO. apobec-1, the catalytic subunit of the mammalian apolipoprotein B mRNA editing enzyme, is a novel RNA-binding protein. J Biol Chem. 1995; 270: 14762-7

15) Yang Y, Sowden MP, Smith HC. Induction of cytidine to uridine editing on cytoplasmic apolipoprotein B mRNA by overexpressing APOBEC-1. J Biol Chem. 2000; 275: 22663-9

16) Harris RS, Bishop KN, Sheehy AM, et al. DNA deamination mediates innate immunity to retroviral infection. Cell. 2003; 113: 803-9

17) Zhang H, Yang B, Pomerantz RJ, et al. The cytidine deaminase CEM15 induces hyper­mutation in newly synthesized HIV-1 DNA. Nature. 2003; 424: 94-8

18) Mangeat B, Turelli P, Caron G, et al. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature. 2003; 424: 99-103

19) Muramatsu M, Sankaranand VS, Anant S, et al. Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells. J Biol Chem. 1999; 274: 18470-6

20) Muramatsu M, Kinoshita K, Fagarasan S, et al. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell. 2000; 102: 553-63

21) Honjo T, Kinoshita K, Muramatsu M. Molecular mechanism of class switch recombination: linkage with somatic hypermutation. Annu Rev Immunol. 2002; 20: 165-96

22) Revy P, Muto T, Levy Y, et al. Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the Hyper-IgM syndrome (HIGM2). Cell. 2000; 102: 565-75

23) Greeve J, Philipsen A, Krause K, et al. Expression of activation-induced cytidine deaminase in human B-cell non-Hodgkin lymphomas. Blood. 2003; 101: 3574-80

24) Heintel D, Kroemer E, Kienle D, et al. High expression of activation-induced cytidine deaminase (AID) mRNA is associated with unmutated IGVH gene status and unfavourable cytogenetic aberrations in patients with chronic lymphocytic leukaemia. Leukemia. 2004; 18: 756-62

25) Ramiro AR, Jankovic M, Eisenreich T, et al. AID is required for c-myc/IgH chromosome translocations in vivo. Cell. 2004; 118: 431-8

26) Okazaki IM, Hiai H, Kakazu N, et al. Constitutive expression of AID leads to tumorigenesis. J Exp Med. 2003; 197: 1173-81

27) Morisawa T, Marusawa H, Ueda Y, et al. Organ-specific profiles of genetic changes in cancers caused by activation-induced cytidine deaminase expression. Int J Cancer. 2008; 123: 2735-40

28) Takai A, Toyoshima T, Uemura M, et al. A novel mouse model of hepatocarcinogenesis triggered by AID causing deleterious p53 mutations. Oncogene. 2009; 28: 469-78

29) Hussain SP, Schwank J, Staib F, et al. TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene. 2007; 26: 2166-76

30) Kou T, Marusawa H, Kinoshita K, et al. Expression of activation-induced cytidine deaminase in human hepatocytes during hepatocarcinogenesis. Int J Cancer. 2007; 120: 469-76

31) Tilg H, Wilmer A, Vogel W, et al. Serum levels of cytokines in chronic liver diseases. Gastroenterology. 1992; 103: 264-74

32) Gonzalez-Amaro R, Garcia-Monzon C, Garcia-Buey L, et al. Induction of tumor necrosis factor alpha production by human hepatocytes in chronic viral hepatitis. J Exp Med. 1994; 179: 841-8

33) Pikarsky E, Porat RM, Stein I, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004; 431: 461-6

34) Karin M, Greten FR. NF-kappaB: linking inflam­mation and immunity to cancer development and progression. Nat Rev Immunol. 2005; 5: 749-59

35) Endo Y, Marusawa H, Kinoshita K, et al. Expres­sion of activation-induced cytidine deaminase in human hepatocytes via NF-kappaB signaling. Oncogene. 2007; 26: 5587-95

36) Marusawa H, Hijikata M, Chiba T, et al. Hepatitis C virus core protein inhibits Fas- and tumor necrosis factor alpha-mediated apoptosis via NF-kappaB activation. J Virol. 1999; 73: 4713-20

37) Peek RM Jr., Blaser MJ. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer. 2002; 2: 28-37

38) Matsumoto Y, Marusawa H, Kinoshita K, et al. Helicobacter pylori infection triggers aberrant expression of activation-induced cytidine deaminase in gastric epithelium. Nat Med. 2007; 13: 470-6

39) Blaser MJ, Perez-Perez GI, Kleanthous H, et al. Infection with Helicobacter pylori strains pos­sessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res. 1995; 55: 2111-5

40) Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990; 61: 759-67

41) Kinzler KW, Vogelstein B. Lessons from heredi­tary colorectal cancer. Cell. 1996; 87: 159-70

42) Yin J, Harpaz N, Tong Y, et al. p53 point mu­tations in dysplastic and cancerous ulcerative colitis lesions. Gastroenterology. 1993; 104: 1633-9

43) Kern SE, Redston M, Seymour AB, et al. Molecu­lar genetic profiles of colitis-associated neo­plasms. Gastroenterology. 1994; 107: 420-8

44) Hussain SP, Amstad P, Raja K, et al. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res. 2000; 60: 3333-7

45) Endo Y, Marusawa H, Kou T, et al. Activation-induced cytidine deaminase links between inflammation and the development of colitis-associated colorectal cancers. Gastroenterology. 2008; 135: 889-98, 898 e1-3

46) Sartor RB. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2006; 3: 390-407

47) Inoue S, Matsumoto T, Iida M, et al. Charac­terization of cytokine expression in the rectal mucosa of ulcerative colitis: correlation with disease activity. Am J Gastroenterol. 1999; 94: 2441-6

48) Takeda K, Tanaka T, Shi W, et al. Essential role of Stat6 in IL-4 signalling. Nature. 1996; 380: 627-30

49) Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol. 2003; 3: 521-33

50) Hebenstreit D, Wirnsberger G, Horejs-Hoeck J, et al. Signaling mechanisms, interaction partners, and target genes of STAT6. Cytokine Growth Factor Rev. 2006; 17: 173-88

51) El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology. 2002; 36: S74-83

52) Fukase K, Kato M, Kikuchi S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endo­scopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet. 2008; 372: 392-7

53) Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology. 2006; 130: 231-64; quiz 214-7

54) Komori J, Marusawa H, Machimoto T, et al. Activation-induced cytidine deaminase links bile duct inflammation to human cholangiocarci­noma. Hepatology. 2008; 47: 888-96

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp